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Abstract: Cancer is one of the most important causes of death worldwide. Solid tumors represent 
the great majority of cancers (>90%) and the chemotherapeutic agents used for their treatment are 
still characterized by variable efficacy and toxicity. Sesquiterpene lactones are a group of naturally 
occurring compounds that have displayed a diverse range of biological activities including 
cytotoxic activity. A series of oxygenated and oxy-nitrogenated derivatives (4–15) from the 
sesquiterpene lactones cumanin (1), helenalin (2), and hymenin (3) were synthesized. The silylated 
derivatives of helenalin, compounds 13 and 14, were found to be the most active against tumor cell 
lines, with GI50 values ranging from 0.15 to 0.59 μM. The ditriazolyl cumanin derivative (11) proved 
to be more active and selective than cumanin in the tested breast, cervix, lung, and colon tumor cell 
lines. This compound was the least toxic against splenocytes (CC50 = 524.1 μM) and exhibited the 
greatest selectivity on tumor cell lines. This compound showed a GI50 of 2.3 μM and a SI of 227.9 on 
WiDr human colon tumor cell lines. Thus, compound 11 can be considered for further studies and 
is a candidate for the development of new antitumor agents. 
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1. Introduction 
According to recent studies, 60% of newly identified chemical entities are natural products, 
semi-synthetic analogs, or synthetic compounds based on their pharmacophores [1]. This occurs 
together with the increased incidence of life-threatening diseases such as AIDS, cancer, hepatitis, etc. 
[2]. It is noteworthy that some semi-synthetic compounds derived from a natural product sometimes 
show higher bioactivity than the original natural compound. Considering the wide range of 
biological activities, such as antiparasitic, antiproliferative, anti-inflammatory, antiviral, 
antibacterial, and antifungal activity, sesquiterpene lactones have attracted scientific interest [3–9]. 
Analyzing the structure of molecules used in cancer therapy, most of them show nitrogenated 
functional groups like amide and carbamate moieties in their framework [10]. Recently, it a series of 
disubstituted 1,2,3-triazoles has been reported exhibiting potent cytotoxicity in the nanomolar range 
and tubulin inhibitory activity in the low micromolar range [11]. This kind of compound is 
considered an interesting unit in the design of anticancer drugs. Such heterocycles may act 
according to their dipolar character, rigidity, and ability to form hydrogen bridge bonds, or simply 
as connectors [12]. 
Synthetic organic chemists have shown great interest in 1,2,3-triazoles for developing new 
biologically active molecules. Triazole moieties do not occur naturally, but 1,2,3-triazole cores may 
form the basis of small-molecule pharmaceutical leads. Molecules containing this heterocyclic 
nucleus have being reported to have anti-HIV, antimicrobial, anti-allergic, antifungal, and antitumor 
activity [13]. 
In a previous work, we reported the cytotoxicity enhancement of some sesquiterpenes and 
iridoids when their lipophilicity was increased by adding alkyl and/or aryl-silyl functionalities on 
the natural framework [12]. 
In consideration of the abovementioned factors, we herein describe our findings aimed at the 
synthesis and cytotoxic evaluation of oxygenated and oxy-nitrogenated derivatives from 
sesquiterpene lactones (STLs) cumanin (1), helenalin (2) and hymenin (3) (Figure 1). It should be 
emphasized that these STLs can be isolated in significant quantities from the natural sources. 
Furthermore, these plants are widely distributed in Argentina [14–16]. 
2. Results and Discussion 
2.1. Chemistry 
The STLs cumanin (1), helenalin (2), and hymemin (3) were isolated from Ambrosia tenuifolia 
Spreng., Gaillardia megapotamica var. megapotamica Spreng., and Parthenium hysterophorus L., 
respectively (Figure 1). 
 
Figure 1. Structures of natural sesquiterpene lactones cumanin (1), helenalin (2), and hymenin (3). 
In preliminary bioactivity tests, these STLs showed significant cytotoxic activity, with helenalin 
being the most active (2). Therefore, STLs have been used as starting materials for the preparation of 
a series of oxygenated and oxo-nitrogenous products; these modifications led to an improved 
activity of the obtained derivatives. In this way, derivatives 4 to 15 were prepared (Figure 2). 





Figure 2. Structures of sesquiterpene lactones derivatives obtained from cumanin (1), helenalin (2), 
and hymenin (3). 
The presence of a hydroxyl group in the structure of the natural compound allowed for the 
preparation of acetylated and silylated derivatives from these STLs. In this regard, the diacetylated 
derivative 4 was prepared under standard conditions from structure 1, and silylated derivatives 5 to 
7 of were obtained under standard conditions and by varying the silylating agent (Scheme 1). The 
silylation reaction of cumanine with TBDPSiCl led to the monosilylated derivative at C3. The 
introduction of this voluminous group resulted in high steric hindrance. NMR, COSY, and HMBC 
analysis allowed for the coupling of H4 (δ = 3.45, dd, J = 8 Hz) with the hydrogen of the hydroxyl 
group of the position 3; HSQC analysis confirms the above since the signal corresponding to OH 
does not show C‒H coupling. HRMS-ES (m/z) analysis: [M + Na]+: Calcd. for C31H40O4Si2Na: 
527.2594; found 527.2586, determines the presence of monosilylated derivative 7. 
Acetylated and silylated derivatives (12 to 15) were prepared from STLs 2 and 3 (Scheme 2). 
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Scheme 1. Synthesis of compounds 4–7. 
 
Scheme 2. Synthesis of compounds 12–15. 
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Synthetic organic chemistry has encouraged great interest in 1,2,3-triazoles in the development 
of new biologically active molecules [12]. The triazole moiety does not occur in nature, but 
1,2,3-triazole cores may form the basis of small-molecule pharmaceutical leads. Molecules 
containing this heterocyclic nucleus have been reported to have anti-HIV, antimicrobial, 
anti-allergic, antifungal, and antitumor activities [12]. One of the most popular reactions within the 
click chemistry paradigm is the Cu (I)-catalyzed 1,3-dipolar Hüisgen cycloaddition of alkynes and 
azides. This reaction proceeds with great efficiency and selectivity in aqueous media and yields 
triazole moieties [17]. Our first objective was to obtain alkynes 8 and 9 using STL 1 as the starting 
material (see Scheme 3). Compound 1 was treated with propargyl bromide and sodium hydride in 
THF to obtain derivatives 8 and 9, and working conditions were optimized in order to increase the 
yield of both products (for the characterization of the propargyl group at C3 see the Supplementary 
Materials). Subsequently, under Hüisgen conditions, 8 and 9 were converted into the corresponding 
mono and di-triazole derivatives 10 and 11, respectively (Scheme 3). 
 
Scheme 3. Synthesis of compounds 8–11. 
2.2. Biological Results 
2.2.1. Antiproliferative Activity 
In vitro antiproliferative activity was evaluated using the protocol of the National Cancer 
Institute (NCI) after 48 h of drug exposure using the sulforhodamine B (SRB) assay. Results, 
expressed as GI50 values, are shown in Table 1. Data revealed that oxygenated derivatives (5–7, 
13–15) are more active than natural products (1–3) with GI50 values ranging from 0.15 to 6.8 μM, in 
all cell lines. Helenalin silylated derivatives 13 and 14 were found to be the most active against all 
tested cell lines, with GI50 values ranging from 0.15 to 0.59 μM. We cannot discard that increasing 
lipophilicity may well result in an increase in cytotoxicity in vitro. 
Most of the cumanin derivatives have shown higher cytotoxic activity than the natural parent 
compound 1. The presence of two 1,2,3-triazole groups in derivative 11 has increased the activity 
values by one order of magnitude compared to cumanin (1). Compounds 4, 8, 9, and 10 displayed 
moderate activity and similar results to 1, with the exception of compounds 8 and 9, which were 
more active than 1 against WiDr cells. 
Hymenin derivative (15) has shown increased activity compared with natural compound 3. 
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Table 1. Antiproliferative activity of the natural sesquiterpene lactones and its derivatives against 
A549, HBL 100, HeLa, SW1573, T47-D, and WiDr cells. Results are expressed as 50% growth 













1 19 (±1.4) 21 (±1.1) 19 (±0.9) 14 (±3.7) 30 (±5.7) 36 (±6.8) 
2 2.3 (±7.8) 2.8 (±1.1) 1.7 (±2) 2.2 (±4.8) 2.9 (±4) 2.7 (±5.1) 
3 9.7 (±0.4) 17 (±0.94) 14 (±0.39) 6.4 (±0.11) 20 (±0.58) 18 (±0.28) 
4 24 (±5.1) * 23 (±5.4) 16 (±2.5) 11 (±2.1) 26 (±4.6) 27 (±5.7) 
5 2.4 (±0.08) **** 3.6 (±0.05) **** 2.9 (±0.01) * 1.8 (±0.02) 1.9 (±0.04) *** 2.2 (±0.37) **** 
6 1.2 (±0.2) **** 2.3(±0.04) **** 1.3 (±0.04) ** 1.2 (±0.02) 2.2 (±0.52) *** 2.4 (±0.41) **** 
7 1.6 (±0.3) **** 3.7 (±0.28) **** 2.0 (±0.28) * 1.5 (±0.2) 3.4 (±0.15) *** 3.1 (±0.44) **** 
8 18 (±1.1) 17 (±1.2) 19 (±13) 28 (±8.6) 24 (±5.8) 7.2 (±3.4) **** 
9 17 (±1.5) 19 (±0.24) 24 (±0.37) 20 (±4.2) 24 (±3.7) 2.1 (±0.2) **** 
10 18 (±1.5) 29 (±7.2) * 32 (±11) 32 (±19) 37 (±13) 30 (±14) 
11 3.7 (±0.9) **** 6.4 (±1.1) *** 5.9 (±0.53) 4.7 (±0.45) 9.7 (±8) *** 2.3 (±0.58) **** 
12 n.d. 3.6 (±0.7) n.d. 4.7 (±3.5) 1.6 (±0.7) n.d. 
13 0.59 (±0.06) 0.36 (±0.07) ** 0.19 (±0.04) 0.28 (±0,02) 0.29 (±0.01) 0.56 (±0.08) 
14 0.28 (±0.02) 0.20 (±0.1) ** 0.15 (±0.02) 0.19 (±0.03) 0.36 (±0.03) 0.26 (±0.2) 
15 3.4 (±0.8) *** 4.6 (±1.1) *** 3.3 (±0.1) **** 2.4 (±0.67) *** 4.2 (±1.0) **** 6.8 (±1.7) *** 
The GI50 mean of each derivative was compared to the activity of its parent compound. For 
compounds 1, 2, and their respective derivatives, a one-way Anova + Dunnett’s test was carried out. 
T-test was used for compound 3 and its derivative. Asterisks indicate significant differences. * p < 
0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. 
2.2.2. Cytotoxicity on Primary Cell Culture Activity 
The cytotoxicity of the sesquiterpene lactones and its derivatives was evaluated using mouse 
splenocytes. Table 2 shows the results of the cytotoxicity assay, as CC50 (the concentration of each 
compound that causes 50% cell death) and the selectivity indexes. Cumanin (1) was the least toxic 
natural compound against splenocytes (CC50 = 29.4 μM) compared with the other sesquiterpene 
lactones (2 and 3). Cumanin derivatives (4–11) have shown CC50 values and selectivity indexes 
higher than natural compound 1. Compounds 4–9 displayed moderate selectivity, while compound 
10 showed low selectivity on the tested cell lines. The incorporation of two triazole groups in 
cumanin (1) reduced cytotoxicity on normal cells and improved selectivity against tumor cell lines. 
Compound 11 was the least toxic against splenocytes (CC50 = 524.1 μM) and presented the greatest 
selectivity on the tested cell lines. This compound showed a GI50 of 2.3 and a SI of 227.9 on human 
colon tumor cell line WiDr. 
Compounds 2 and 3, as well as their corresponding derivatives, displayed a low selectivity of 
action against tumor cell lines. Similar results have been obtained for compound 12 by Lee et al. [18]. 
Table 2. Cytotoxicity and selectivity indexes of natural sesquiterpene lactones and their derivatives. 





A549 HBL100 HeLa SW1573 T47-D WiDr 
1 29.4 (±0.2) 1.5 1.4 1.5 2.1 1.0 0.8 
2 1.2 (±0.3) 0.5 0.4 0.7 0.5 0.4 0.4 
3 4.4 (±0.8) 0.4 0.3 0.3 0.7 0.2 0.2 
4 240.8 (±3.8) **** 10.0 10.5 15.0 21.9 9.3 8.9 
5 66.4 (±0.4) *** 27.7 18.4 22.9 36.9 34.9 30.2 
6 91.8 (±0.5) **** 76.5 39.9 70.6 76.5 41.7 38.2 
7 142.7 (±1.5) **** 89.2 38.6 71.3 95.1 42.0 46.0 
8 180.6 (±5.4) **** 10.0 10.6 9.5 6.4 7.5 25.1 
9 93.5 (±8.9) **** 5.5 4.9 3.9 4.7 3.9 44.5 
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10 113.6 (±12.0) **** 6.3 3.9 3.5 3.5 3.1 3.8 
11 524.1 (±4.0) **** 141.6 81.9 88.8 111.5 54.0 227.9 
12 0.4 (±0.1) n.d. 0.1 n.d. 0.1 0.2 n.d. 
13 1.1 (±0.3) 1.9 3.0 5.8 3.9 3.8 2.0 
14 1.4 (±0.2) 5.0 7.0 9.3 7.4 3.9 5.4 
15 2.3 (±0.7) 0.7 0.5 0.7 0.9 0.5 0.3 
The CC50 mean of each derivative was compared to the activity of its parent compound. For 
compounds 1, 2, and their respective derivatives, a one-way Anova + Dunnett’s test was carried out. 
T-test was used for compound 3 and its derivative. Asterisks indicate significant differences. * p < 
0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. 
3. Materials and Methods 
3.1. General 
Unless otherwise stated, all solvents were purified by standard techniques. Reactions requiring 
anhydrous conditions were performed under an argon atmosphere. Anhydrous magnesium sulfate 
was used for drying solutions. Reactions were monitored by thin-layer chromatography (TLC) on 
silica gel plates (60 F254) (Merck KGaA, Darmstadt, IN, USA), and visualized with UV light, 2.5% 
phosphomolybdic acid in ethanol, or vanillin with acetic and sulfuric acid in ethanol with heating. 
Purification was performed by column chromatography (CC) on silica gel (230–400 mesh) using 
n-hexane and ethyl acetate gradient as solvent. 1H NMR spectra were recorded on a Bruker (Bruker 
Biospin GmbH, Silberstreifen, Rheinstetten, Germany) 200, 500, or 600 MHz, 13C NMR spectra were 
recorded at 50 and 125 M Hz, and chemical shifts are reported relative to internal Me4Si (δ = 0). 
Melting points were determined by using an Electrothermal IA9000 melting point apparatus; results 
are reported in degrees Celsius and are uncorrected. Optical rotations were recorded on a 343 Perkin 
Elmer polarimeter (Waltham, MA, USA). High-resolution ESI mass spectra were obtained from a 
Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometer, a RF-only hexapole ion 
guide, and an external electrospray ion source. HRMS spectra were obtained on a Micromass 
AutoSpec (Oakville, ON, Canada) mass spectrometer. 
3.2. Plant Material 
The species used in the present work were Ambrosia tenuifolia Spreng. (Asteraceae), Gaillardia 
megapotamica var. megapotamica (Asteraceae), and Parthenium hysterophorus (Asteraceae). 
The aerial parts of Ambrosia tenuifolia Spreng. (Asteraceae) were collected in May 2010 in Ibicuy, 
Entre Ríos Province, Argentina. The material was identified by Dr. Gustavo Giberti and the 
Herbarium specimen is deposited in the Museum of Pharmacobotany at the Faculty of Pharmacy 
and Biochemistry, University of Buenos Aires (BAF 717). 
Gaillardia megapotamica var. megapotamica Spreng. (Asteraceae) was collected in November 1989 
in the city of La Arenilla, San Luis Province, and identified by Prof. Eng. Luis del Vitto. The 
specimens are registered as Del Vito & Petenatti under No. 4633, and deposited at the Herbarium of 
the National University of San Luis. 
Parthenium hysterophorus (Asteraceae) was collected in March 1988 in the town of San Roque, 
department of La Capital, Province of San Luis, and identified by Prof. Eng. Luis del Vitto. They are 
registered under the numbers 1672-UNSL, and the Herbarium specimens are deposited in the 
National University of San Luis. 
In all cases the aerial parts were collected, dried at room temperature to a constant weight, 
manually fragmented or ground, as appropriate, and placed in plastic bags from which the oxygen 
was removed and replaced by argon inert gas for storage until the moment of processing. 
3.3. Sesquiterpene Lactone Extraction and Isolation 
3.3.1. Isolation of Cumanin from A. tenuifolia 
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Extraction conditions: 1.25 kg of aerial parts dried at room temperature to constant weight were 
processed. The plant material was extracted with acetone (3 × 48 h) at room temperature and the 
organic extracts were concentrated in vacuo. The residue (30 g) was collected and chromatographed 
in a 63-cm, 7 cm diameter column, using Sigel 60 G (70–230 mesh) (Merck KGaA, Darmstadt, IN, 
USA) and eluting with n-hexane-EtOAc mixtures of increasing polarity [16]. 
Under these conditions, 6 g of cumanin (1) were obtained in the fractions eluted with hexane: 
ethyl acetate 2:8. These values represent a yield of 4.8 g of cumanin per kg of dry plant. 
3.3.2. Isolation of Helenalin from G. megapotámica var. megapotámica 
The dried to constant weight aerial parts (1.50 kg) of G. megapotamica var megapotamica were 
extracted (3 × 48 h) with MeOH at room temperature. The organic extracts were combined and 
concentrated in a rotary evaporator. The dry extract was solubilized in 1 L of a mixture of MeOH: 
H2O (8:2) and stored in a refrigerator overnight. After this cooling time, the organic phase was 
separated and the aqueous phase was washed with MeOH (3 × 500 mL). The organic phases were 
combined, and solvent was removed by rotary evaporator [18]. Thirty-five grams of dry extract were 
recovered and chromatographed on a 65-cm length and 7 cm in diameter column, using as 
stationary phase of Sigel 60 G (70–230 mesh) and eluting with n-hexane:EtOAc mixtures of 
increasing polarity. After two separative processes in CC, 10.2 g of helenalin (2) were obtained, 
representing a yield of 6.8 g per kg of dry plant. 
3.3.3. Extraction and Purification of Hymenin from P. hysterophorus 
For preparing the crude extract of the dried to constant weight aerial parts of P. hysterophorus, 
1.10 kg of plant material was used and extracted by maceration at room temperature with CHCl3 for 
24 h. The maceration was filtered and the extract was taken to dryness in a rotary evaporator. 
Subsequently, the dried extract was solubilized in hot EtOH and left overnight at room temperature. 
Then, it was filtered and the ethanolic solution was extracted with CHCl3 (4 × 150 mL). The organic 
phase was dried over anhydrous Na2SO4 and filtered, and the solvent was removed under reduced 
pressure at a temperature lower than 40 °C until 20 g of a gummy-like dry residue was obtained [18]. 
The fractionation was carried out by preparative CC (65 × 7 cm) using Sigel 60G (70–230 mesh) as 
stationary phase and eluting with mixtures of n-hexane and EtOAc of increasing polarities. After the 
chromatographic separation, 3.4 g of hymenin (3) were obtained, representing a yield of 3.1 g per kg 
of dry plant. 
3.4. Chemistry 
Preparation of derivative 4: compound 1 (50 mg) (1 eq., 0.188 mmol) of 1 was dissolved in 1 mL 
of pyridine (0.2 M) and 1 mL of acetic anhydride (50 eq., 9.4 mmol) was added. The reaction was 
monitored by TLC after extraction with EtOAc in acid medium. After 6 h, the reaction was complete 
and quenched by pouring in saturated copper sulfate solution and extracting with ethyl acetate (3 × 
50 mL each)., The organic phase was washed with distilled water (3 × 25 mL each), dried with 
anhydrous sodium sulfate, and concentrated under reduced pressure. Under these conditions, 49 
mg of the derivative 4 was recovered as a white solid, yield 75%. 
Preparation of derivative 5: compound 1 (50 mg) (1 eq., 0.187 mmol) was dissolved in 1.5 mL of 
Cl2CH2 (0.1 M), 45 mg (3.5 eq., 0.658 mmol) of imidazole, and 69 mg of TMSiCl (0.08 mL, 0.657 mmol) 
were added; reaction was carried out at room temperature and confirmed by TLC to be complete 
after 3 h. The reaction was quenched with a concentrated solution of (NH4)2SO4 (40 mL) and 
extracted with Et2O (3 × 20 mL). The organic phase was washed with water (30 mL) and dried with 
Na2SO4, filtered, concentrated, and purified by isocratic CC (30 × 0.5 cm) using Sigel 60 G (70–230 
mesh), as stationary phase, and a mixture of n-hexane-EtOAc (60:40) as a mobile phase to give 48 mg 
of compound 5 as a yellow solid, yield 63%. 
Preparation of derivative 6: compound 1 (50 mg) (1 eq., 0.187 mmol) was dissolved in 1.5 mL of 
Cl2CH2 (0.1 M), 45 mg (3.5 eq., 0.657 mmol) of imidazole and 87 mg of DMISOPSiCl (0.1 mL, 0.657 
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mmol) were added; the reaction was carried out at room temperature and confirmed by TLC to be 
complete after 1 h. The reaction was quenched with a concentrated solution of (NH4)2SO4 (40 mL) 
and extracted with Et2O (3 × 20 mL). The organic phase was washed with water (30 mL) and dried 
with Na2SO4, filtered, concentrated, and purified by isocratic CC (30 × 0.5 cm) using Sigel 60 G 
(70–230 mesh), as stationary phase, and a mixture of n-hexane:EtOAc (50:50) as mobile phase to give 
51 mg of compound 6 as a yellow solid, yield 58%. 
Preparation of derivative 7: compound 1 (50 mg) (1 eq., 0.187 mmol) was dissolved in 1.5 mL of 
Cl2CH2 (0.1 M), 45 mg (3.5 eq., 0.657 mmol) of imidazole and 211 mg TBDPSiCl (0.2 mL, 0.657 mmol) 
were added; reaction was carried out at room temperature. The reaction was confirmed to be 
complete by TLC after 4 h. The reaction was quenched with a concentrated solution of (NH4)2SO4 (40 
mL) and extracted with Et2O (3 × 20 mL). The organic phase was washed with water (30 mL) and 
dried with Na2SO4, filtered, concentrated, and purified by CC (30 × 0.5 cm) using Sigel 60 G (70–230 
mesh), as stationary phase and 160 mL of a mixture of n-hexane:EtOAc (80:20) and 320 mL of a 
mixture of n-hexane:EtOAc (70:30) as mobile phase to give 43 mg of compound 7 as a yellow solid, 
yield 45%.  
Preparation of derivative 8: compound 1 (100 mg) (1 eq., 0.188 mmol) was dissolved in 5 mL of 
dry THF (0.04 M), and 144 mg (10 eq., 3,82 mmol) of sodium hydride (60% in mineral oil) was added. 
The mixture was stirred for 60 min in Ar atmosphere. Subsequently, 277.6 mg (1 eq., 0.752 mmol) of 
TBAI and 134 mg of propargyl bromide (3 eq., 0.10 mL; 1.128 mmol) were added. The reaction was 
confirmed to be complete after 4 h, and was quenched with water and extracted with ethyl acetate (2 
× 50 mL). The organic phases were combined, dried with Na2SO4, filtered, concentrated, and purified 
by CC (30 × 0.5 cm) using Sigel 60G (70–230 mesh) as stationary phase and 120 mL of CH2Cl2 and 280 
mL of CH2Cl2:EtOAc (95:5) as mobile phase to give 40 mg of 8 as a white solid, yield 35%. 
Preparation of derivative 9: compound 1 (100 mg) (1 eq., 0.382 mmol) of 1 was dissolved in 5 mL 
of dry THF (0.04 M), 144 mg (10 eq., 3.82 mmol) of sodium hydride (60% in mineral oil) was added. 
The mixture was stirred for 60 min in Ar atmosphere. Subsequently, 277.6 mg (1 eq., 0.752 mmol) of 
TBAI and 186 mg of propargyl bromide (6 eq., 0.20 mL, 2.292 mmol) were added. The reaction was 
confirmed by TLC to be complete after 4 h. The reaction was quenched with water and extracted 
with ethyl acetate (2 × 50 mL). The organic phases were combined, dried with Na2SO4, filtered, 
concentrated and purified by CC (30 × 0.5cm) using Sigel 60G (70–230 mesh) as stationary phase and 
120 mL of CH2Cl2 and 280 mL of CH2Cl2:EtOAc (95:5) as mobile phase to give 28 mg of 9 as a white 
solid, yield 21%. 
Preparation of derivative 10: compound 8 (31.7 mg) (1 eq., 0.104 mmol) of 8 was dissolved in 3 
mL (0.2 M) of a 1:1 ethanol/water mixture at room temperature, 18.84 mg of benzyl azide (1 eq., 0.104 
mmol),1.67 mg of CuSO4.5H2O (0.1 eq., 0.0104 mmol), and 6.18 mg sodium ascorbate (0.3 eq., 0.0312 
mmol) were added. The reaction was confirmed by TLC to be complete after 96 h. The reaction was 
quenched with 20 mL of water and extracted with ethyl ether (3 × 30 mL). The organic phase was 
dried with Na2SO4, filtered, concentrated under reduced pressure, and purified by CC using Sigel 
60G (70–230 mesh) as stationary phase and a mixture of n-hexane:EtOAc (50:50) as mobile phase to 
give 21.6 mg of 10 as a white amorphous solid. Yield 47%. 
Preparation of derivative 11: To obtain dithriazole 11, compound 9 (20 mg) (1eq., 0.03 mmol) 
was dissolved in 1 mL (0.1 M) of a 1:1 ethanol/water mixture at room temperature, and 15 mg of 
benzyl azide was added (1 eq., 0.03 mmol), then 1 mg of CuSO4.5H2O (0.1 eq., 0.003 mmol) and 3.29 
mg of sodium ascorbate (0.3 eq., 0.009 mmol) were also added. The reaction was confirmed by TLC 
to be complete after 96 h. The reaction was quenched with 20 mL of water and extracted with ethyl 
ether (3 × 30 mL). The ether phase was dried with Na2SO4, filtered, concentrated under reduced 
pressure. Then, it was purified by CC of Sigel 60G (70–230 mesh) using a mixture of 
n-hexane:EtOAc: (40:60) as mobile phase to give 8.9 mg (yield 21.9%) of compound 11 as a white 
amorphous solid. 
Preparation of derivative 12: 50 mg (1 eq., 0.190 mmol) of helenalin (2), 1 mL (50 eq., 9.5 mmol) 
of acetic anhydride, and 1 mL (0.2M) of pyridine were stirred at room temperature. The reaction was 
confirmed to be complete by TLC after 6 h. The reaction was quenched with saturated copper sulfate 
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solution and extracted with ethyl acetate (3 × 50 mL). The organic phase was washed with water (3 × 
25 mL), dried with Na2SO4, and concentrated under reduced pressure. Then, it was purified by CC of 
Sigel 60G (70–230 mesh) using n-hexane:EtOAc (40:60) as mobile phase. Forty-two milligrams of 12 
were obtained (yield 70%) as an amorphous solid. 
Preparation of derivative 13: 50 mg (1 eq., 0.190 mmol) of helenalin (2), and 45 mg (3.5 eq., 0.667 
mmol) of imidazole, were dissolved in 1.5 mL (0.1.M) of Cl2CH2, at room temperature. After 15 min 
of stirring, 0.08 mL (3.5 eq.; 0.667 mmol) of TMSiCl was added. After 6 h, the reaction was complete. 
The reaction was quenched with 40 mL of ammonium chloride solution and extracted with ethyl 
ether (3 × 20 mL). The organic phase was washed with water (30 mL) and dried with Na2SO4, 
filtered, concentrated, and purified in CC (30 × 0.5 cm) of Silicagel 60G (70–230 mesh) using a 
mixture of n-hexane:EtOAc (50:50) as eluent. Thirty-five milligrams (yield 56%) of 13 were obtained 
as an amorphous solid. 
Preparation of derivative 14: 50 mg (1 eq., 0.190 mmol) of 2 and 45 mg (3.5 eq., 0.667 mmol) of 
imidazole were dissolved in 1.5 mL (0.1M) of Cl2CH2 at room temperature. After 15 min of stirring, 
0.1 mL (3.5 eq.; 0.667mmol) of DMISOPSiCl was added. After 10 h, the reaction was complete. The 
reaction was quenched with 40 mL of an oversaturated ammonium chloride solution and 
subsequently extracted with ethyl ether (3 × 20 mL). The organic phase was washed with water (30 
mL) and dried with Na2SO4, filtered, concentrated, and purified in CC (30 × 0.5 cm) of Silicagel 60G 
(70–230 mesh) using a mixture of n-hexane:EtOAc (50:50) as eluent. 34.5 mg (yield 50%) of 14 was 
obtained as an amorphous solid. 
Preparation of derivative 15: 100 mg of hymenin (3) (1 eq., 0.351 mmol) and 84 mg (3.5 eq., 1.23 
mmol) of imidazole in 1.5 mL of dichloromethane were dissolved at room temperature. After 15 min 
of stirring, 0.2 mL (3.5 eq., 1.23 mmol) TMSiCl was added. The reaction lasted 72 h. After this time, 
the reaction was poured into 40 mL of ammonium chloride solution and extracted with ethyl ether (3 
× 20 mL). The organic phase was washed with water (30 mL) and dried with Na2SO4, filtered, 
concentrated, and purified by CC (30 × 0.5 cm) of silica gel 60G (70–230 mesh) using n-hexane:EtOAc 
(30:70) as eluent; 44.6 mg of 18 (yield 35%) were obtained as an amorphous solid. 
3.5. Spectroscopic and Physical Data 
Compound 1: White solid, m.p. 122–124 °C. [α]
20
 D: +144.3 (c 11.73; CHCl3). IR (KBr; υmax: cm−1): 
3412, 1745, 2908, 1275, 984. 1H-NMR (δ = ppm, 600M Hz): 1.41 (1H, ddd, J = 13 and 7 Hz, H-1); 
1.66–1.73 (1H, td, J = 13 and 5 Hz, H-2a); 2.05–2.11 (1H, m, H-2b); 4.21 (1H, td, J = 8 and 5 Hz, H-3); 
3.51 (1H, d, J = 8 Hz, H-4); 1.59 (1H, t, J = 15, H-6a); 1.95 (1H, dd, J = 4 and 15 Hz, H-6b); 3.13 (1H, m, 
H-7); 4.68 (1H, dtd, J = 12 and 5 Hz, H-8); 1.77 (1H, c, J = 12 Hz, H-9a); 2.13–2.18 (1H, m,H-9b); 
1.97–2.03 (1H, m, H-10); 5.61 (1H, d, J = 3 Hz, H-13); 6.26 (1H, d, J = 3 Hz, H-13′); 1.04 (3H, d, J = 7 Hz, 
H-14); 0.98 (3H, s, H-15). 13C-NMR (δ = ppm, 150M Hz): 41.6 (C-1); 35.3 (C-2); 68.4 (C-3); 77.1 (C-4); 
44.3 (C-5); 40.7 (C-6); 37.8 (C-7); 80.1 (C-8); 36.7 (C-9); 30.4 (C-10); 139.8 (C-11); 169.9 (C-12); 123.0 
(C-13); 16.7 (C-14); 17.8 (C-14). HRMS-ES m/z: [M + Na]+: Calcd. for C15H22O4Na: 289.1416; found: 
289.1422. 
Compound 2: White solid, m.p. 159–161 °C. [α]
20
 D: −64.56 (c 12.33; CHCl3). IR (KBr; υmax: cm−1): 
3342, 2927, 1699, 1757, 1111, 962. 1H-NMR (δ = ppm, 200M Hz): 7.52 (1H, d, J = 6 Hz, H-2); 6.19 (1H, d, 
J = 6 Hz, H-3); 4.85 (1H, d, J = 9 Hz, H-6); 3.25 (1H, m, H-7); 2.00–2.10 (1H, m, H-8); 1.71–1.79 (1H, m, 
H-9a); 1.71–1.79 (1H, m, H-9b); 1.71–1.79 (1H, m, H-10); 5.54 (1H, d, J = 3 Hz, H-13); 6.26 (1H, d, J = 4 
Hz, H-13′); 1.13 (3H, d, J = 6 Hz, H-14); 1.06 (3H, s, H-15). 13C-NMR (δ = ppm, 50M Hz): 83.2 (C-1); 
164.0 (C-2); 130.6 (C-3); 208.3 (C-4); 57.5 (C-5); 79.8 (C-6); 41.8 (C-7); 25.8 (C-8); 31.7 (C-9); 37.8 (C-10); 
138.9 (C-11); 170.4 (C-12); 120.8 (C-13); 17.7 (C-14); 14.8 (C-15). HRMS-ES (m/z): [M + Na]+: Calcd. for 
C15H18O4Na: 285.1103; found 285.1107. 
Compound 3: White solid, m.p. 173–174 °C. [α]
20
 D: −78.69 (c 11.17; CHCl3). IR (KBr; υmax: cm−1): 
3450, 2972, 1741, 1282, 976. 1H-NMR (δ = ppm, 200M Hz): 7.52 (1H, d, J = 6 Hz, H-2); 6.19 (1H, d, J = 6 
Hz, H-3); 4.85 (1H, d, J = 9 Hz, H-6); 3.25 (1H, m, H-7); 2.00–2.10 (1H, m, H-8); 1.71–1.79 (1H, m, 
H-9a); 1.71–1.79 (1H, m, H-9b); 1.71–1.79 (1H, m, H-10); 5.54 (1H, d, J = 3 Hz, H-13); 6.26 (1H, d, J = 4 
Hz, H-13′); 1.13 (3H, d, J = 6 Hz, H-14); 1.06 (1H, s, H-15). 13C-NMR (δ = ppm, 50M Hz): 83.2 (C-1); 
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164.0 (C-2); 130.6 (C-3); 208.3 (C-4); 57.5 (C-5); 79.8 (C-6); 41.8 (C-7); 25.8 (C-8); 31.7 (C-9); 37.8 (C-10); 
138.9 (C-11); 170.4 (C-12); 120.8 (C-13); 17.7 (C-14); 14.8 (C-15). HRMS-ES (m/z): [M + Na]+: Calcd. for 
C15H18O4Na: 285.1103; found 285.1107. 
Compound 4: White solid, m.p.: 85–86 °C. [α]
20
 D: +57.7 (c 4.92; CHCl3). IR (KBr; υmax: cm−1): 2966, 
1755, 1743, 1250, 1066, 823, 598. 1H-NMR (δ = ppm, 200M Hz): 1.50–1.59 (1H, m, H-1); 1.71–1.91 (1H, 
m, H-2a); 2.10–2.27 (1H, m, H-2b); 5.25 (1H, ddd, J = 8 and 15 Hz, H-3); 4.78 (1H, d, J = 8 Hz, H-4); 1.60 
(1H, s, H-6a); 1.67 (1H, m, H-6b); 3.2 (1H, m, H-7); 4.68 (1H, ddd, J = 8 and 16 Hz, H-8); 1.66–1.87 (1H, 
m, H-9a); 2.15–2.27 (1H, m, H-9b); 2.01–2.07 (1H, m, H-10); 5.56 (1H, d, J = 2 Hz, H-13); 6.25 (1H, d, J = 
2 Hz, H-13′); 1.05 (3H, d, J = 7 Hz, H-14); 1.07(1H, s, H-15); 2.04 (3H, s, H-2′); 2.07 (3H, s, H-2″). 
13C-NMR (δ = ppm, 50M Hz): 41.3 (C-1); 32.3 (C-2); 69.2 (C-3); 75.7 (C-4); 43.9 (C-5); 39.9 (C-6); 37.6 
(C-7); 79.4 (C-8); 36.2 (C-9); 29.8 (C-10); 139.4 (C-11); 169.5 (C-12); 123.2 (C-13); 16.6 (C-14); 18.5 (C-15); 
170.2 (C-1′); 20.8 (C-2′); 170.6 (C-1″); 20.6 (C-2″). HRMS-ES (m/z): [M + Na]+: Calcd. for C19H26O6Na: 
373.1627; found 373.1635. 
Compound 5: Yellow solid, m.p.: 98–100 °C. [α]
20
 D: +121.5 (c 9.1; CHCl3). IR (KBr; υmax: cm-1): 
2958, 2927, 1747, 1466, 1379, 1250, 1169, 1086. 1H-NMR (δ = ppm, 200M Hz): 1.31–1.41 (1H, m, H-1); 
1.52–1.69 (1H, m, H-2a); 2.17 (1H, ddd, J = 4, 8 and 12 Hz, H-2b); 4.07 (1H, ddd, J = 4 and 7 Hz, H-3); 
3.42 (1H, d, J = 7 Hz, H-4); 1.52–1.69 (1H, m, H-6a); 1.73–1.88 (1H, m, H-6b); 3.10 (1H, m, H-7); 4.67 
(1H, dtd, J = 8 and 11 Hz, H-8); 1.73–1.88 (1H, m, H-9a); 1.90–2.08 (1H, m, H-9b); 1.90–2.08 (1H, m, 
H-10); 5.53 (1H, d, J = 2 Hz, H-13); 6.26 (1H, d, J = 2 Hz, H-13′); 1.04 (3H, d, J = 7 Hz, H-14); 0.99 (3H, s, 
H-15); 0.13* (9H, s, H-1′, H-2′ and H-3′); 0.17*(9H, s, H-1″, H-2″ and H-3″). 13C-NMR (δ = ppm, 50M 
Hz): 41.1 (C-1); 36.8 (C-2); 69.7 (C-3); 78.1 (C-4); 44.6 (C-5); 40.4 (C-6); 37.7 (C-7); 79.9 (C-8); 36.5 (C-9); 
30.3 (C-10); 140.2 (C-11); 169.8 (C-12); 122.3 (C-13); 16.6 (C-14); 18.5 (C-15); 0.40* (C-1′, C-2′ and C-3′); 
0.50* (C-1″, C-2″ and C-3″). HRMS-ES (m/z): [M + Na]+: Calcd. for C21H38O4Si2Na: 433.2206; found 
433.2209. 
Compound 6: Yellow solid, m.p.: 50–52 °C. [α]
20
 D: +104.41 (c 9.97; CHCl3). IR (KBr; υmax: cm−1): 
2960, 2899, 1747, 1464, 1385, 1248, 1173, 1088. 1H-NMR (δ = ppm, 200M Hz): 1.31–1.39 (1H, m, H-1); 
1.63–1.77 (1H, m, H-2a); 1.88–2.06 (1H, m, H-2b); 4.06 (1H, cd, J = 7 Hz, H-3); 3.4 (1H, d, J = 7 Hz, H-4); 
1.52–1.57 (m, H6a); 1.76–1.88 (m, H6b); 3.09 (m, H7); 4.65 (ddd, J = 8 and 11 Hz, H8); 1.76–1.88 (m, 
H9a); 2.09–2.23(1H, m, H-9b); 1.88–2.06 (1H, m, H-10); 5.51 (1H, d, J = 3 Hz, H-13); 6.24 (1H, d, J = 3 
Hz, H-13′); 1.02 (3H, d, J = 5 Hz, H-14); 0.98 (3H, s, H-15); -0,01(6H, s, H-1′ and H-2′); 0.61* (3H, d, J = 8 
Hz, H-4′); 0.63* (3H, d, J = 8 Hz, H-5′); -0,01(6H, s, H-1″ and H-2″); 0.61* (3H, d, J = 8 Hz, H-4″); 0.63* 
(3H, d, J = 8 Hz, H-5″). 13C-NMR (δ = ppm, 50M Hz): 41.2 (C-1); 36.8 (C-2); 69.7 (C-3); 78.2 (C-4); 44.8 
(C-5); 40.4 (C-6); 37.8 (C-7); 80.0 (C-8); 36.5 (C-9); 30.3 (C-10); 140.3 (C-11); 169.8 (C-12); 122.3 (C-13); 
16.5 (C-14); 18.5 (C-15); -0,01 (C-1′, 2′ and 3′); 17.1 (C-4′); 17.0 (C-5′); −0,01 (C-1″, 2″ and 3″); 17.1 (C-4″); 
17.0 (C-5″). HRMS-ES (m/z): [M + Na]+: Calcd. for C25H46O4Si2Na: 489.2832; found 489.2825. 
Compound 7: Yellow solid, m.p.: 70–72 °C. [α]
20
 D: +42.28 (c 10.36; CHCl3). IR (KBr; υmax: cm−1): 
3537, 2962, 1763, 1427, 1267, 1113, 702. 1H-NMR (δ = ppm, 200M Hz): 1.23–1.29 (1H, m, H-1); 
1.50–1.62 (1H, m, H-2a); 1.50–1.62 (1H, m, H-2b); 4.25 (1H, dd, J = 8 Hz, H-3); 3.45 (1H, dd, J = 8 Hz, 
H-4); 1.50–1.62 (1H, m, H-6a); 1.93–2.04 (1H, m, H-6b); 3.09 (1H, m, H-7); 4.58 (1H, ddd, J = 8 and 11 
Hz, H-8); 1.70–1.79 (1H, m, H-9a); 2.06–2.18 (1H, m, H-9b); 1.80–1.91 (1H, m, H-10); 5.58 (1H, d, J = 2 
Hz, H-13); 6.24 (1H, d, J = 2 Hz, H-13′); 0.95 (3H, d, J = 7 Hz, H-14); 1.05 (3H, s, H-15); 1.11 (9H, s, H-2′, 
H-3′ and H-4′); 7.63 (8H, m, H-2″ and H-3″); 7.43 (2H, m, H-4″). 13C-NMR (δ = ppm, 50M Hz): 41.1 
(C-1); 35.8 (C-2); 70.3 (C-3); 77.0 (C-4); 44.3 (C-5); 40.6 (C-6); 37.6 (C-7); 79.7 (C-8); 36.4 (C-9); 30.0 
(C-10); 139.8 (C-11); 169.9 (C-12); 122.8 (C-13); 16.6 (C-14); 17.8 (C-15); 0.2 (C-1′); 27.2 (C-2′); 133.4 
(C-1″); 127.8 (C-2″); 135.9 (C-3″); 130.1 (C-4″). HRMS-ES (m/z): [M + Na]+: Calcd. for C31H40O4Si2Na: 
527.2594; found 527.2586. 
Compound 8: White solid, m.p.: 100–101 °C. [α]
20
 D +30.3 (c 4.84; CHCl3). IR (KBr; υmax: cm−1): 3523, 
3278, 2918, 2114, 1761, 1385, 1269, 1120, 1086, 997. 1H-NMR (δ = ppm, 600M Hz): 1.45 (1H, m, H-1); 
1.75–1.82 (1H, m, H-2a); 2.05–2.12 (1H, m, H-2b); 4.26 (1H, m, H-3); 3.47 (1H, d, J = 7 Hz, H-4); 1.60 
(1H, t, J = 1, 4 and 7 Hz, H-6a); 1.95–2.01 (1H, m, H-6b); 3.16 (1H, m, H-7); 4.68 (1H, ddd, J = 8 and 11 
Hz, H-8); 1.72–1.81 (1H, m, H-9a); 2.15–2.20 (1H, m, H-9b); 1.95–2.01 (1H, m, H-10); 5.55 (1H, s, H-13); 
6.26 (1H, d, J = 2 Hz, H-13′); 1.04 (3H, d, J = 7 Hz, H-14); 1.02 (3H, s, H-15); 4.36 (1H, d, J = 2 Hz, H-1′a); 
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4.33 (1H, d, J = 2 Hz, H-1′b); 2.5 (1H, s, H-3′). 13C-NMR (δ = ppm, 150M Hz): 41.6 (C-1); 35.1 (C-2); 66.5 
(C-3); 83.9 (C-4); 44.2 (C-5); 40.7 (C-6); 38.0 (C-7); 79.9 (C-8); 36.4 (C-9); 30.2 (C-10); 140.2 (C-11); 169.8 
(C-12); 122.7 (C-13); 16.6 (C-14); 18.8 (C-15); 58.5 (C-1′); 75.2 (C-2′); 80.0 (C-3′). HRMS-ES (m/z): [M + 
Na]+: Calcd. for C18H24O4Na: 327.1572; found 327.1574. 
Compound 9: White solid, m.p.: 125–126 °C. [α]
20
 D: +59.0 (c 5.73; CHCl3). IR (KBr; υmax: cm−1): 3431, 
2927, 2355, 2119, 1759, 1387, 1273, 1088, 997. 1H-NMR (δ = ppm, 600M Hz): 1.48 (1H, m, H-1); 
1.74–1.85 (1H, m, H-2a); 2.055–2.12 (1H, m, H-2b); 4.25 (1H, m, H-3); 3.62 (1H, d, J = 7 Hz, H-4); 1.60 
(1H, t, J = 15 Hz, H-6a); 1.97–2.04 (1H, m, H-6b); 3.18 (1H, m, H-7); 4.69 (1H, ddd, J = 8 and 11 Hz, 
H-8); 1.74–1.85 (1H, m, H-9a); 2.16–2.22 (1H, m, H-9b); 1.97–2.04 (1H, m, H-10); 5.58 (1H, s, H-13); 
6.26 (1H, s, H-13′); 1.05 (3H, d, J = 7 Hz, H-14); 1.04 (3H, s, H-15); 4.43 (1H, d, J = 16 Hz, H-1′a); 4.30 
(1H, d, J = 1 6 Hz, H-1′b); 2.46 (1H, brs, H-3′); 4.22 (1H, d, J = 16 Hz, H-1″a); 4.16 (1H, d, J = 16 Hz, 
H-1″b); 2.42 (1H, brs, H-3″). 13C-NMR (δ = ppm, 150M Hz): 41.4 (C-1); 32.9 (C-2); 72.2 (C-3); 81.7 (C-4); 
44.0 (C-5); 40.1 (C-6); 37.8 (C-7); 79.8 (C-8); 36.4 (C-9); 30.2 (C-10); 140.0 (C-11); 169.7 (C-12); 122.6 
(C-13); 16.6 (C-14); 18.4 (C-15); (57.0C-1′); 80.2 (C-2′); 74.5 (C-3′); 56.4 (C-1″); 79.7 (C-2″); 74.3 (C-3″) 
HRMS-ES (m/z): [M + Na]+: Calcd. for C21H26O4Na: 365.1729; found 365.1729. 
Compound 10: White amorphous solid, m.p.: 74–75 °C. [α]
20
 D: +10.5 (c 3.80; CHCl3). IR (KBr; υmax: 
cm−1): 3433, 2924, 2360, 1757, 1637, 1456, 1205, 1076, 725. 1H-NMR (δ = ppm, 600M Hz): 1.41–1.45 (1H, 
m, H-1); 1.72–1.79 (1H, m, H-2a); 2.07–2.11 (1H, m, H-2b); 4.15 (1H, m, H-3); 3.52 (1H, d, J = 7 Hz, 
H-4); 1.51 (1H, t, J = 15 Hz, H-6a); 1.68 (1H, dd, J = 15 Hz, H-6b); 3.07 (1H, m, H-7); 4.64 (1H, ddd, J = 3 
and 8- Hz, H8); 1.72–1.79 (1H, m, H-9a); 2.13–2.19 (1H, m, H-9b); 1.94–1.99 (1H, m, H-10); 5.43 (1H, d, 
J = 2 Hz, H-13); 6.2 (1H, d, J = 2 Hz, H-13′); 1.03 (3H, d, J = 7 Hz, H-14); 1.00 (3H, s, H-15); 4.75 (2H, d, J 
= 12, H-1′); 7.53 (1H, s, H-3′); 5.56 (2H, d, J = 3, H-1″); 7.40 (2H, m, H-3″ and H-5″); 7.30 (1H, m, H-4″). 
13C-NMR (δ = ppm, 150M Hz): 41.3 (C-1); 34.9 (C-2); 66.3 (C-3); 84.4 (C-4); 44.2 (C-5); 40.7 (C-6); 37.8 
(C-7); 79.8 (C-8); 36.3 (C-9); 30.0 (C-10); 139.8 (C-11); 169.7 (C-12); 122.7 (C-13); 16.6 (C-14); 18.7 (C-15); 
63.8 (C-1′); 145.1 (C-2′); 122.7 (C-3′); 54.4 (C-1″); 134.2 (C-2″); 129.3 (C-3″); 128.2 (C-4″); 129.0 (C-5″). 
HRMS-ES (m/z): [M + Na]+: Calcd. for C25H31N3O4Na: 460.2212; found 460.2217. 
Compound 11: White amorphous solid, m.p.: 80–81 °C. [α]
20
 D: +7.3 (c 1.79; CHCl3). IR (KBr; υmax: 
cm−1): 3433, 2962, 2924, 1757, 1456, 1261, 1092, 1120, 800. 1H-NMR (δ = ppm, 600M Hz): 1.37–1.42 (1H, 
m, H-1); 1.71–1.77 (1H, m, H-2a); 2.01–2.04 (1H, m, H-2b); 3.96–4.00 (1H, m, H-3); 3.45 (1H, d, J = 7 Hz, 
H-4); 1.68 (1H, dd, J = 15 Hz, H-6a); 1.71–1.77 (1H, m, H-6b); 3.03 (1H, m, H-7); 4.61–4.65 (1H, m, H-8); 
1.71–1.77 (1H, m, H-9a); 2.13–2.18 (1H, m, H-9b); 1.95–1.98 (1H, m, H-10); 5.43 (1H, d, J = 2 Hz, H-13); 
6.19 (1H, d, J = 2 Hz, H-13′); 1.01 (3H, d, J = 7 Hz, H-14); 0.99 (3H, s, H-15); 4.64–4.67 (2H, m, H-1′a) / 
4.65–4.71 (2H, m, H-1′a); 4.47 (2H, d, J = 12, H-1′b) / 4.54 (2H, d, J = 12, H-1′b); 7.61 (2H, s, H-3′a); 7.58 
(1H, s, H-3′b); 5.58 (d, J = 10, H-1″a); 5.54 (d, J = 10, H-1″b); 7.29–7.40 (10H, m, H-3″, H-4″ and H-5″). 
13C-NMR (δ = ppm, 150M Hz): 41.0 (C-1); 33.2 (C-2); 73.9 (C-3); 83.6 (C-4); 44.3 (C-5); 40.3 (C-6); 37.8 
(C-7); 79.8 (C-8); 36.3 (C-9); 30.1 (C-10); 139.7 (C-11); 169.8 (C-12); 122.9 (C-13); 16.7 (C-14); 18.5 (C-15); 
62,3 (C-1′a); 63.2 (C-1′b); 145.2 (C-2′a); 145.3 (C-2′b); 123.1 (C-3′a); 123.4 (C-3′b); 54.5 (C-1″); 134.4 
(C-2″); 128.3 (C-3″); 129.2 (C-4″); 129.0 (C-5″). HRMS-ES (m/z): [M + Na]+: Calcd. for C35H40N6O4Na: 
631.3009; found 631.3015. 
Compound 12: Amorphous solid, m.p.: 164–165 °C. [α]
20
 D: −76.3 (c 9.3; CHCl3). IR (KBr; υmax: 
cm−1): 2927, 2854, 1767, 1734, 1709, 1657, 1466, 1238, 949. 1H-NMR (δ = ppm, 200M Hz): 3.02 (1H, dt, J 
= 3 and 2 Hz, H-1); 7.65 (1H, dd, J = 2 and 6 Hz, H-2); 6.07 (1H, dd, J = 3 and 6 Hz, H-3); 5.38 (1H, br s, 
H-6); 3.51 (1H, ddd, J = 8 and 12, H-7); 4.88 (1H, ddd, J = 2 and 7 Hz, H-8); 1.75 (1H, cd, J = 19 Hz, 
H-9a); 2.43 (1H, m, H-9b); 2.07–2.18 (1H, m, H-10); 6.14 (1H, d, J = 3 Hz, H-13); 6.45 (1H, d, J = 3 Hz, 
H-13′); 1.27 (3H, d, J = 7 Hz, H-14); 1.01 (3H, s, H-15); 2.00 (3H, brs, H-2′). 13C-NMR (δ = ppm, 50M 
Hz): 53.2 (C-1); 162.1 (C-2); 129.7 (C-3); 208.9 (C-4); 55.4 (C-5); 77.6 (C-6); 47.7 (C-7); 78.1 (C-8); 40.2 
(C-9); 26.1 (C-10); 137.4 (C-11); 169.7 (C-12); 125.0 (C-13); 20.0 (C-14); 18.4 (C-15); 169.5 (C-1′); 21.0 
(C-2′). HRMS-ES (m/z): [M + Na]+: Calcd. for C17H20O5Na: 327.1208; found 327.1215. 
Compound 13: Amorphous solid. m.p.: 82–84 °C. [α]
20
 D: −41.6 (c 11.2; CHCl3). IR (KBr; υmax: cm−1): 
2960, 2929, 1761, 1714, 1464, 1246, 1109, 845. 1H-NMR (δ = ppm, 200M Hz): 3.20 (1H, dt, J = 6 and 12 
Hz, H-1); 7.64 (1H, dd, J = 2 and 6 Hz, H-2); 5.99 (1H, dd, J = 3 and 6 Hz, H-3); 4.42 (1H, d, J = 2 Hz, 
H-6); 3.30 (1H, m, H-7); 4.95 (1H, td, J = 3 and 8 Hz, H-8); 1.78 (1H, cd, J = 8 Hz, H-9a); 2.30 (1H, m, 
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H-9b); 2.22–2.33 (1H, m, H-10); 5.76 (1H, d, J = 3 Hz, H-13); 6.36 (1H, d, J = 3 Hz, H1–3′); 1.24 (3H, d, J 
= 7 Hz, H-14); 0.9 (3H, s, H-15); 0.11 (9H, s, H-1′, H-2′ and H-3′). 13C-NMR (δ = ppm, 50M Hz): 51.5 
(C-1); 163.4 (C-2); 129.2 (C-3); 210.8 (C-4); 57.6 (C-5); 76.0 (C-6); 51.7 (C-7); 78.7 (C-8); 40.1 (C-9); 26.0 
(C-10); 138.1 (C-11); 170.0 (C-12); 122.9 (C-13); 20.1 (C-14); 18.4 (C-15); 0.4 (C-1′, 2′ and 3′). HRMS-ES 
(m/z): [M + Na]+: Calcd. for C18H26O4SiNa: 357.1498; found 357.1492. 
Compound 14: Amorphous solid, m.p.: 50–52 °C. [α]
20
 D: −33.9 (c 9.85; CHCl3). IR (KBr; υmax: cm−1): 
2958, 2922, 2364, 1770, 1718, 1464, 1269, 1090, 858. 1H-NMR (δ = ppm, 200M Hz): 3.21 (1H, dt, J = 3 
and 2 Hz, H-1); 7.64 (1H, dd, J = 2 and 6 Hz, H-2); 5.98 (1H, dd, J = 3 and 6 Hz, H-3); 4.42 (1H, d, J = 2 
Hz, H-6); 3.39 (1H, m, H-7); 4.92 (1H, td, J = 3 and 8 Hz, H-8); 1.76 (1H, cd, J = 8 Hz, H-9a); 2.33 (1H, 
m, H-9b); 2.1 (1H, m, H-10); 5.74 (1H, d, J = 3 Hz, H-13); 6.36 (1H, d, J = 3 Hz, H-13′); 1.23 (3H, d, J = 7 
Hz, H-14); 0.88 (3H, s, H-15); 0.12*(3H, s, H-1′); 0.44*(3H, s, H-2′); 0.94 (1H, s, H-3′); 0.84*(3H, s, H-4′); 
0.90*(3H, s, H-5′). 13C-NMR (δ = ppm, 50M Hz): 51.8 (C-1); 163.2 (C-2; 129.2 (C-3); 210.7 (C-4); 57.8 
(C-5); 76.1 (C-6); 51.5 (C-7); 78.7 (C-8); 40.3 (C-9); 26.0 (C-10); 138.1 (C-11); 170.0 (C-12); 123.0 (C-13); 
20.1 (C-14); 18.5 (C-15); −3.6* (C-1′); -3.8* (C-2′); 29.7 (C-3′); 16.8 (C-4′ and 5′). HRMS-ES (m/z): [M + 
Na]+: Calcd. for C20H30O4SiNa: 385.1811; found 385.1819. 
Compound 15: Amorphous solid, m.p.: 150–151 °C. [α]
20
 D: −94.3 (c 5.23; CHCl3). IR (KBr; υmax: 
cm−1): 2960, 2927, 1763, 1714, 1468, 1379, 1053, 847. 1H-NMR (δ = ppm, 200M Hz): 7.52 (1H, d, J = 6 Hz, 
H-2); 6.19 (1H, d, J = 6 Hz, H-3); 4.83 (1H, d, J = 9 Hz, H-6); 3.23 (1H, m, H-7); 1.92–2.05 (1H, m, H-8); 
1.62–1.69 (1H, m, H-9); 1.62–1.69 (1H, m, H-10); 5.50 (1H, d, J = 3 Hz, H-13); 6.26 (1H, d, J = 4 Hz, 
H-13′); 1.05 (3H, d, J = 5 Hz, H-14); 1.03 (3H, s, H-15); 0.15 (9H, brs, H-1′, H-2′ and H-3′). 13C- NMR (δ 
= ppm, 50M Hz): 86.5 (C-1); 163.0 (C-2); 131.0 (C-3); 207.6 (C-4); 58.2 (C-5); 79.7 (C-6); 41.8 (C-7); 25.6 
(C-8); 32.2 (C-9); 38.9 (C-10); 170.0 (C-11); 139.1 (C-12); 120.3 (C-13); 17.7 (C-14); 15.4 (C-15); 2.6 (C-1′, 
2′ and 3′). HRMS-ES (m/z): [M + Na]+: Calcd. for C18H26O4SiNa: 357.1498; found 357.1502. 
3.6. Cells, Culture, and Plating 
The following human solid tumor cell lines were used in this study: HBL-100 (breast), HeLa 
(cervix), SW1573 (non-small cell lung), T-47D (breast), A549 (lung), and WiDr (colon). Cells were 
maintained in 25 cm2 culture flasks in RPMI 1640 supplemented with 5% heat-inactivated fetal calf 
serum and 2 mM L-glutamine in a 37 °C, 5% CO2, 95% humidified air incubator. Exponentially 
growing cells were trypsinized and resuspended in antibiotic containing medium (100 units 
penicillin G and 0.1 mg of streptomycin per mL). Single-cell suspensions displaying >97% viability 
by trypan blue dye exclusion test were subsequently counted. After counting, dilutions were made 
to give the appropriate cell densities for inoculation onto 96-well microtiter plates. Cells were 
inoculated in a volume of 100 μL per well at densities of 20,000 (WiDr), 15,000 (T-47D and A549), and 
10,000 (HeLa, SW1573, and HBL-100) cells per well, based on their doubling times. 
3.7. Antiproliferative Tests 
Chemosensitivity tests were performed using the SRB assay of the NCI with slight 
modifications. Briefly, pure compounds were initially dissolved in DMSO at 400 times the desired 
final maximum test concentration. Control cells were exposed to an equivalent concentration of 
DMSO (0.25% v/v, negative control). Each agent was tested in triplicate at different dilutions in the 
range 1–100 μM. Drug treatment started on day 1 after plating. Drug incubation periods were 48 h, 
after which cells were precipitated with 25 μL of ice-cold 50% (w/v) trichloroacetic acid and fixed for 
60 min at 4 °C. Then, the SRB assay was performed. Optical density (OD) of each well was measured 
at 492 nm, using BioTek’s PowerWave XS Absorbance Microplate Reader (Highland Park, Winooski, 
VT, USA). Values were corrected for background OD from wells containing only culture medium. 
The percentage growth (PG) was calculated with respect to untreated control cells (C) at each level of 
drug concentrations based on the difference in OD at the start time (T0) and at the end of drug 
exposure (T), according to NCI formulas. Therefore, if T is greater than or equal to T0, the calculation 
is 100 × [(T–T0)/(C–T0)]. If T is lower than T0, denoting cell death, the calculation is 100 × 
[(T–T0)/(T0)]. The effect is defined as the growth percentage, where 50% growth inhibition (GI50) 
represents the concentration at which PG is +50. Based on these calculations, a PG value of 0 
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corresponds to the number of cells present at the beginning of drug exposure, while negative PG 
values denote net cell death. 
3.8. Cytotoxicity on Primary Cell Culture 
In a 96-well plate, spleen cells from Balb/c mouse (1.5 × 105) were incubated with different drug 
dilutions (200, 100, 50, 10, and 5 μg/mL) in RPMI medium containing 10% fetal calf serum. After 48 h 
of incubation at 37 °C (5% CO2), cells were harvested, washed once with PBS, and stained with 2.5 
μg/mL propidium iodide (PI) for 5 min at room temperature. Subsequently, cell death was assessed 
by flow cytometry using a BD FACSaria II cytometer. Cells incubated only with a drug vehicle were 
used as a 100% viability control and death percentage was calculated according to the following 
formula: 
    ℎ(%)  =   1 −
(%        )            
(%        )   %                  
  × 100.  
Then the concentration capable of causing cell death in 50% of splenocytes (CC50) was 
determined using a non-linear regression approach. 
3.9. Statistical Analysis 
Results are presented as means ± SD. GraphPad Prism 5.0 software (GraphPad Software Inc., 
San Diego, CA, USA) was employed to carry out calculations. The results account for three to four 
independent experiments. 
4. Conclusions 
Given these results, using natural compounds can be a viable strategy to prepare new active 
molecules. Sesquiterpene lactones were the starting material for their transformation into several 
oxygenated and oxo-nitrogenated derivatives by chemical reactions aiming at the hydroxylated 
positions. Our strategy was to obtain new derivatives, including functionalities such as acetates, silyl 
ethers, and 1,2,3-triazoles. Although sesquiterpene lactones showed interesting antiproliferative 
activity values, a significant number of these synthetic derivatives showed greater activity than the 
naturally occurring parent product. Many of the synthesized analogs were more selective toward 
tumor cell lines than normal cells. Compound 11, the ditriazolyl cumanin derivative, proved to be 
more active and selective than cumanin in the tested breast, cervix, lung, and colon tumor cell lines. 
Thus, this compound can be considered for further studies and is a possible candidate for 
developing new antitumor agents. 
Finally, this work aims at illustrating the possibility of obtaining new naturally-occurring 
anti-tumor leads from molecular frameworks, some of which exhibit significantly improved 
bioactivity just by common chemical transformations. 
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